European Medicines Agency confirms positive benefit-risk balance of Rotarix

View source ↗

Summary

The EMA confirms a positive benefit–risk balance for Rotarix, supporting its continued use and approval status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Gastroenteritis

Drugs mentioned

• Rotarix (Rotavirus vaccine (live attenuated))